09/47 - Deficit di glucosio fosfato deidrogenasi e farmaci.Donatella Maffi, Maria Pia Caforio, Maria Teresa Pasquino, Patrizia Caprari2009, 31 p.

Glucose-6-phosphate dehydrogenase deficiency and drugs.
Donatella Maffi, Maria Pia Caforio, Maria Teresa Pasquino, Patrizia Caprari
2009, 31 p. (in Italian)

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a X-linked hereditary disease due to a mutation in the gene coding the G6PD. The enzyme takes part in the pentose phosphate pathway and his function is to control the erythrocyte redox potential. The clinical manifestation is the acute haemolytic anaemia triggered by an oxidative stress. Oxidative drugs are the most important haemolytic factor in G6PD deficient people. The evaluation of the drug haemolytic potential is complicated because the risk of drug-induced G6PD deficiency-related haemolysis depends on a number of factors and the clinical trials in G6PD deficient people are very difficult to set up. In this work a review of previously reported list (Rapporti ISTISAN 99/19) of the potentially haemolytic drugs for G6PD deficient people has been performed.
Key words: Glucose-6-phosphate dehydrogenase deficiency, G6PD, Haemolytic anaemia, Drugs, Oxidative stress